`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`BRECKENRIDGE PHARMACEUTICAL, INC.
`
`Petitioner
`
`V.
`
`NOVARTIS PHARMACEUTICALS CORPORATION
`
`Patent Owner
`
`Case IPR2017—01592
`
`U.S. Patent No. 8,410,131
`
`
`DECLARATION OF FU L. LUAN, M.D.
`
`Breckenridge Exhibit 1119
`Luan Declaration
`
`Breckenridge v. Novartis IPR 2017-01592
`
`
`
`I, Fu L. Luan, declare as follows:
`
`I.
`
`I am a transplant nephrologist affiliated with the Saint Barnabas
`
`Medical Center located at 94 Old Short Hills Road, Livingston, NJ 07039.
`
`2.
`
`I am being compensated for my time connected with this matter at my
`
`hourly rate of$174.00/hr.
`
`3.
`
`I am the first—named author of Abstract# 428 entitled "Sirolimus
`
`Prevents Tumor Progression: mTOR Targeting For The Inhibition Of Neoplastic
`
`Progression" (the ”Luan Abstract”) the results of which were presented at a joint
`
`meeting of the American Society of Transplantation and the American Society of
`
`Transplant Surgeons (”Transplant 2001”) held in Chicago, Illinois on May 11—16,
`
`2001.
`
`4.
`
`I received a Young Investigators Award based on the results presented
`
`in the Luan Abstract.
`
`5.
`
`I understand that the Luan Abstract is found at page 001 of EX. 1005
`
`filed in the above-styled Inter Partes Review (IPR2017-0 1 5 92).
`
`6.
`
`The Luan Abstract was included in a "Program Book" containing all
`
`abstracts to be presented during Transplant 2001. The Program Book was entitled
`
`"Transplant 2001: The Joint American Transplant Meeting," and it was provided to
`
`attendees of Transplant 2001.
`
`7.
`
`The Luan Abstract was publicly available as a printed publication at the
`
`time of the Transplant 2001 meeting in May of 2001.
`
`l
`
`Breckenridge Exhibit 1119
`Luan Declaration
`
`Breckenridge v. Novartis IPR 2017-01592
`
`
`
`I declare under penalty of perjury under the laws of the United States of
`
`America that the foregoing is true and correct.
`
`Dated: January 19, 2018
`
`
`
`fl"
`
`Fu L. Luan, MD.
`
`Breckenridge Exhibit 1119
`Luan Declaration
`
`Breckenridge v. Novartis IPR 2017-01592
`
`